NICE has recommended a first-of-its-kind therapy that can delay the onset of type 1 diabetes for up to three years, opening the way for access on the NHS in England. The guidance marks an important development for people at high risk of the condition, which can otherwise progress quickly and require lifelong insulin treatment.
The recommendation was published on 23 June 2026 and describes the therapy as the first disease-modifying treatment of its kind to be made available on the NHS for delaying the onset of type 1 diabetes. NICE said the treatment could give patients more time before the condition develops, potentially changing the way clinicians manage the disease in its earliest stages. NICE news articles
Why the recommendation matters for early intervention
Type 1 diabetes is usually associated with the need for ongoing treatment once it develops, so a therapy that can postpone onset is being viewed as a notable shift in care. NICE said the treatment can delay disease onset for up to three years, offering a window in which patients may avoid or postpone the burden of active disease management.
The guidance follows a period of rapid activity in diabetes-related care across NICE. In recent months, the organisation has also highlighted other diabetes technologies and treatments, including a pregnancy-specific artificial pancreas device and other new NHS options for people living with diabetes. NICE guidance
A broader shift toward disease-modifying care
While treatment for type 1 diabetes has traditionally focused on managing blood glucose after diagnosis, this recommendation points toward earlier intervention in the disease process. NICE described the therapy as disease-modifying, signalling a focus on delaying the condition rather than only treating its effects after onset.
For patients, that could mean more time before starting intensive diabetes care. For clinicians, it adds another option in a field where early-stage treatment choices have been limited. The recommendation is also likely to draw attention from health services watching how preventive and delaying therapies may reshape demand in long-term disease management.
NICE’s announcement sits alongside a wider stream of recent NHS-facing decisions on serious conditions, from cancer treatments to neurological disease therapies, as the organisation continues to update guidance on interventions that could improve outcomes or extend time to progression. More NICE news
With the new recommendation, type 1 diabetes joins a growing list of conditions where the NHS may soon be able to act earlier in the disease course. The move is likely to be closely watched by patients, diabetes specialists and policymakers looking for ways to reduce the long-term impact of chronic disease.
